---
document_datetime: 2023-09-21 21:56:14
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/neurobloc-epar-procedural-steps-taken-authorisation_en.pdf
document_name: neurobloc-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3795615
conversion_datetime: 2025-12-23 03:28:24.31547
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The company Elan Pharma International Ltd. submitted on 26 July 1999 an application for Marketing Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for NeuorBloc, through the centralised procedure. After agreement by the CPMP on 26-29 January 1999, this  medicinal  product  has  been  referred  to  Part  B  of  the  Annex  to  Council  Regulation  No  (EEC) 2309/93 of 22 July 1993.

•

The Rapporteur and Co-Rapporteur appointed by the CPMP were: Rapporteur: Prof. C. Sampaio Co-Rapporteur: Dr. David Lyons Licensing status: The product was not licensed in any country at the time of submission of the application. 2. Steps taken for the assessment of the product · The procedure started on 27 August 1999. · The Rapporteur's first assessment report was circulated to all CPMP Members on 8 November 1999.    The  Co-Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members  on 9 November 1999. · The CPMP at its meeting of 16-18 November 1999 decided that there was a need for a GMP inspection of the active substance and finished product manufacturing sites of NeuroBloc. · During  the  meeting  on  14-16  December  1999  the  CPMP  agreed  on  the  consolidated  list  of questions to be sent to the company.  The final consolidated list of questions was sent to the Applicant on 15 December 1999. · The  Applicant  submitted  the  responses  to  the  CPMP  consolidated  list  of  questions  on 23 March 2000.  The clock restarted on 14 April 2000. · The Rapporteur circulated the response assessment report on the Applicant's responses to the list of questions to all CPMP Members on 15 May 2000. · During the CPMP meeting on 27-29 June 2000, the CPMP issued a list of outstanding questions to be addressed by the Applicant during an oral explanation. · The Applicant submitted to the EMEA and the CPMP members on 16 August 2000 background documentation for the oral explanation. · On  19  September  2000,  the  Applicant  addressed  the  outstanding  issues  during  an  oral explanation before the CPMP. · During the meeting on 19-21 September 2000, the Applicant was requested to provide further data  (protocol  of  a  post-marketing  study  comparing  efficacy  and  safety  of  NeuroBloc  versus Botulinum Toxin Type A) prior to the October CPMP meeting.  The CPMP decided that the protocol should be discussed during the October CPMP Scientific Advice group meeting and that feedback on the protocol should be given to the October CPMP. Medicinal product no longer authorised

- The Applicant submitted to the EMEA and the CPMP members on 3 October 2000 the Protocol Synopsis for the proposed post marketing commitment study.
- During  the  meeting  on  17-19  October  2000,  in  the  light  of  the  overall  data  submitted,  the scientific discussion within the Committee and the feedback from the Scientific advice group on the  protocol  submitted  by  the  Applicant,  the  Committee  issued  a  positive  opinion  under exceptional circumstances for granting a Marketing Authorisation to NeuroBloc on 19 October 2000.